Immunopathogenic Treatment Options for Psoriasis Patients Under a Restrictive Reimbursement Environment
, , et | 22 juil. 2021
À propos de cet article
Publié en ligne: 22 juil. 2021
Pages: 158 - 166
Reçu: 11 juin 2020
Accepté: 01 mars 2021
DOI: https://doi.org/10.2478/prolas-2021-0025
Mots clés
© 2020 Ilona Hartmane et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is aimed to provide an overview of psoriasis clinical aspects, available treatment options for moderate-to-severe psoriasis in Baltics and summarises recommendations of authors for use of different biologicals in psoriasis patients under a limited reimbursement environment.